INS and Alzheimer disease: ‐>To assess safety and efficacy of either singular and combined effects of IN insulin (Humulin R U‐100) and Empagliflozin, to correct bioenergetic and vascular dysfunction in adults with preclinical or early AD and amnestic MCI over a 4‐week treatment period